0.5
Cite Score
SJR: 0.129 / SNIP: 0.140
JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
Volume 15, Issue 2 (2023)
3 2023, 15(2): 177-180 |
Back to browse issues page
History
Received: 2023/02/9 | Accepted: 2023/04/16 | Published: 2023/05/26
Received: 2023/02/9 | Accepted: 2023/04/16 | Published: 2023/05/26
How to cite this article
Hayder Ewad H, Basheer A, Omairi S, Lafta M, Mahdi M. Canagliflozin-associated Peripheral Vascular Ischemia: A Case Report. 3 2023; 15 (2) :177-180
URL: http://ijwph.daneshafarand.org/article-3-85521-en.html
URL: http://ijwph.daneshafarand.org/article-3-85521-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Acute Medicine, College of Medicine, University of South Wales, Wales, UK
2- Department of Internal Medicine, Collage of Medicine, Wasit University, Kut, Iraq
3- Department of Anatomy and Biology, College of Medicine, Wasit University, Kut, Iraq
4- Department of Internal Medicine, College of Medicine, Baghdad University, Baghdad, Iraq
2- Department of Internal Medicine, Collage of Medicine, Wasit University, Kut, Iraq
3- Department of Anatomy and Biology, College of Medicine, Wasit University, Kut, Iraq
4- Department of Internal Medicine, College of Medicine, Baghdad University, Baghdad, Iraq
Abstract (2189 Views)
Aims: Sodium-glucose transporter inhibitors 2 are a new drug group used for patients with diabetes mellitus. These are a very effective group in the management of type 2 diabetes, but side effects such as urinary tract infections and foot ulcers do appear, which is specific to canagliflozin. Therefore, the current case report focuses on patients taking canagliflozin who presented with foot and leg ulcers.
Patient & Methods: The patient was a 69-year-old man who went to the hospital after falling at home and was diagnosed with pneumonia and lower limb ulcers. The patient had a history of ischemic heart disease, chronic kidney disease, multiple sclerosis and type 2 diabetes mellitus (regarding canagliflozin). A complete laboratory examination was performed, and appropriate treatment was done, but unfortunately the patient died due to multiple comorbidities.
Findings: It seems that the risk of peripheral vascular ischemia is increased in type 2 diabetes patients taking canagliflozin. This case was mainly highlighted to confirm the fact that using canagliflozin is associated with increased incidence of lower limb amputation, particularly toes.
Conclusion: There may be is a relationship between canagliflozin and lower limb ulcers in patients with type 2 diabetes mellitus who are older than 65 years.
Patient & Methods: The patient was a 69-year-old man who went to the hospital after falling at home and was diagnosed with pneumonia and lower limb ulcers. The patient had a history of ischemic heart disease, chronic kidney disease, multiple sclerosis and type 2 diabetes mellitus (regarding canagliflozin). A complete laboratory examination was performed, and appropriate treatment was done, but unfortunately the patient died due to multiple comorbidities.
Findings: It seems that the risk of peripheral vascular ischemia is increased in type 2 diabetes patients taking canagliflozin. This case was mainly highlighted to confirm the fact that using canagliflozin is associated with increased incidence of lower limb amputation, particularly toes.
Conclusion: There may be is a relationship between canagliflozin and lower limb ulcers in patients with type 2 diabetes mellitus who are older than 65 years.
Keywords: